PDE5A and heart failure: These results help explain the lack of a therapeutic effect in recent clinical trials examining the inhibition of PDE5 in patients with heart failure [15,16], which highlights the importance of the rigorous demonstration of the protein targeted by therapy in the normal and diseased heart prior to clinical trial design.